Research Projects & Grants

• Emergency use of Venetoclax, Role: PI, Status: Completed
• Individual patient program (IPP) use of Trametinib and Dabrafenib for Multisystem Langerhands Cell Histiocytosis, Role: Investigator, (11/2019) Status: Completed

College/University

• Intrathecal 2-Hydroxypropyl-ß-cyclodextrin for neurological decline in patients with Niemann-Pick disease type C1, Role: Investigator, Rush University Medical Center, (12/2024 - 12/2025) Status: Approved
• POEM: A PrOspective Registry of Pediatric Cellular Therapy Patients at risk for Endothelial Dysfunction, Sinusoidal Obstruction Syndrome and/or Multi-Organ Dysfunction Syndrome (MODS), Role: Investigator, Duke University, (12/2024 - 12/2025) Status: Approved

Federal

• COG-APEC14B1: project: EveryChild - a registry, eligibility screening, biology and outcome study, Role: PI, Children Oncology Group, (09/2024 - 09/2025) Status: Approved
• COG A031102: a randomized phase III trial comparing conventional-dose chemotherapy using paclitaxel, ifosfamide, and cisplatin (TIP) with high-dose chemotherapy using mobilizing paclitaxel plus Ifosfamide followed by high-dose carboplatin and etoposide (TI-CE) as first salvage treatment in relapsed or refractory germ cell tumors, Role: PI, Children Oncology Group, (09/2024 - 09/2025) Status: Approved
• COG AAML 1921 / ITCC-054: A Phase I/II study of Bosutinib in pediatric patients with newly diagnosed chronic phase or resistant/intolerant Ph+ Chronic Myeloid Leukemia, Role: PI, Children Oncology Group, (08/2024 - 08/2025) Status: Approved
• COG AALL1631: International phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones, Role: PI, Children Oncology Group, (07/2024 - 07/2025) Status: Approved
• COG ACNS1422: A Phase 2 Study of reduced therapy for newly diagnosed average-risk WNT-driven medulloblastoma patients, Role: PI, Children Oncology Group, (06/2024 - 06/2025) Status: Approved
• TSLP and pediatric leukemia mechanisms and treatment, Role: Investigator, National Cancer Institute/NIH/DHHS, (06/2024 - 06/2025) Status: Approved
• COG - AALL03B1 - Classification of Acute Lymphoblastic Leukemia consent for collection of additional bone marrow, Role: PI, Children Oncology Group, (06/2024 - 07/2024) Status: Completed
• COG AALL1621: phase 2 study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in children and young adults with relapsed or refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL), Role: PI, Children Oncology Group, (06/2024 - 06/2025) Status: Approved
• COG- AREN03B2 - renal tumors classification, biology and banking study, Role: PI, Children Oncology Group, (06/2024 - 06/2025) Status: Approved
• COG - ACCRN07: Protocol for the Enrollment on the Official Registry, the Childhood Cancer Research Network (CCRN)., Role: PI, Children Oncology Group, (04/2025 - 04/2026) Status: Approved
• COG-ANBL00B1 Neuroblastoma biology studies Revised 11/30/2000, Role: PI, Children Oncology Group, (03/2025 - 03/2026) Status: Approved
• COG ARST1431: A randomized phase 3 study of vincristine, dactinomycin, cyclophosphamide (VAC) alternating with vincristine and irinotecan (VI) versus VAC/VI plus temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in patients with intermediate risk (IR) rhabdomyosarcoma (RMS), Role: PI, Children Oncology Group, (03/2025 - 03/2026) Status: Approved
• COG AEWS1221: Randomized phase 3 trial evaluating the addition of the IGF-1R monoclonal antibody ganitumab (AMG 479, NSC# 120449) to multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma, Role: PI, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
• COG AAML1331: A phase III study for patients with newly diagnosed acute promyelocytic Leukemia (APL) using arsenic trioxide and all trans-retinoic acid, Role: PI, Children Oncology Group, (02/2025 - 02/2026) Status: Approved
• Children's Oncology Group (COG)-AALL0932: Treatment of patients with newly diagnosed standard risk B-precursor acute lymphoblastic leukemia (ALL) or localized B-lineage lymphoblastic lymphoma (B-LLy), Role: PI, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
• COG - ACNS0334: A phase III randomized trial for the treatment of newly diagnosed supratentorial PNET and high risk medulloblastoma in children < 36 months old with intensive induction chemotherapy with methotrexate followed by consolidation with stem cell rescue vs. the same therapy without methotrexate, Role: PI, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
• Children's Oncology Group (COG) - ACNS0831: Phase III randomized trial of post-radiation chemotherapy in patients with newly diagnosed ependymoma ages 1 to 21 years, Role: PI, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
• Children's Oncology Group (COG) - AEWS1031: A phase III randomized trial of adding vincristine-topotecan-cyclophosphamide to standard chemotherapy in initial treatment of non-metastatic Ewing sarcoma, Role: PI, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
• COG-AAML1031: A phase III randomized trial for patients with de novo AML using Bortezomib (IND# 58443, NSC#681239) and Sorafenib (BAY 43-9006, IND#69896, NSC# 724772) for patients with high allelic ratio FLT3/ITD, Role: PI, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
• COG AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B- Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND #73789, NSC #732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations, Role: PI, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
• COG AALL1231: A phase III randomized trial investigating Bortezomib (NSC#681239; IND#58443) on a modified augmented BFM (ABFM) backbone in newly diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy), Role: PI, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
• Children's Oncology Group (COG) AALL1331: Risk-stratified randomized phase III testing of blinatumomab (IND#117467, NSC#765986) in first relapse of childhood B-Lymphoblastic Leukemia (B-ALL), Role: PI, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
• COG AHOD 1331: randomized phase III study of Brentuximab Vedotin (SGN-35, IND #117117) for newly diagnosed high-risk classical Hodgkin Lymphoma (cHL) in children and adolescents, Role: PI, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
• COG AGCT1531: A phase 3 study of active surveillance for low risk and a randomized trial of carboplatin vs. cisplatin for standard risk pediatric and adult patients with germ cell tumors, Role: PI, Children Oncology Group, (02/2025 - 02/2026) Status: Approved
• COG: AALL0434 - Intensified methotrexate, nelarabine (compound 506U78; IND# 52611) and augmented BFM therapy for children and young adults with newly diagnosed T-cell acute lymphoblastic leukemia or T-Cell Lymphoblastic Lymphoma, Role: PI, Children Oncology Group, (01/2025 - 03/2025) Status: Completed
• COG-ACNS0332: A study evaluating the efficacy of carboplatin administered concomitantly with radiation and isotretinoin as a pro-apoptotic agent in other than average risk medulloblastoma/PNET patients, Role: PI, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
• Children's Oncology Group (COG) - AALL0631: A Phase III study of risk directed therapy for infants with acute lymphoblastic leukemia (ALL): Randomization of highest risk infants to intensive chemotherapy +/- FLT3 inhibition (CEP-701, lestaurtinib; IND#76431; NSC#617807), Role: PI, Children Oncology Group, (02/2024 - 07/2024) Status: Completed
• COG- AHOD0831: A non-randomized phase III study of response adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin's Lymphoma, Role: PI, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
• COG-AREN0534: Treatment for patients with bilateral, multicentric, or bilaterally-predisposed unilateral Wilms tumor, Role: PI, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
• COG - ANBL0032 - Phase III randomized study of Chimeric antibody 14.18 (Ch14.18) in high risk Neuroblastoma following Myeloablative Therapy and autologous stem cell rescue, Role: PI, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
• COG: AREN0533 - Treatment of newly diagnosed higher risk favorable histology Wilms tumors, Role: PI, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
• Children's Oncology Group (COG) - ALTE05N1: Umbrella long-term follow-up protocol, Role: PI, Children Oncology Group, (11/2024 - 11/2025) Status: Approved
• COG AAML1531: Risk-stratified therapy for acute myeloid leukemia in Down Syndrome, Role: PI, Children Oncology Group, (10/2024 - 10/2025) Status: Approved
• Children's oncology group (COG)-AALL08B1: Classification of newly diagnosed acute lymphoblastic leukemia (ALL), Role: PI, Children Oncology Group, (10/2023 - 10/2024) Status: Completed
• Children's Oncology Group (COG) - AAML08B1: biology study of Transient Myeloproliferative Disorder (TMD) in children with Down Syndrome (DS), Role: PI, Children Oncology Group, (05/2023 - 05/2024) Status: Completed
• Children’s Oncology Group (COG) protocol AOST06B1 – collecting and banking osteosarcoma specimens, Role: PI, Children Oncology Group, (05/2023 - 05/2024) Status: Completed
• COG AOST1421: A phase 2 study of human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 (Dinutuximab, NSC #764038, IND #4308) in combination with sargramostim (GM-CSF) in patients with recurrent osteosarcoma, Role: PI, Children Oncology Group, (03/2023 - 03/2024) Status: Completed
• COG – ARST0332: Risk-Based Treatment for Non-Rhabdomyosarcoma Sort Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age, Role: PI, Children Oncology Group, (03/2023 - 02/2024) Status: Completed
• COG-ANBLOOP3 - A Phase II/III study of the use of intravenous gammaglobulin therapy for patients with neuroblastoma associated opsoclonus-myoclonus-ataxia syndrome, Role: PI, Children Oncology Group, (04/2022 - 04/2023) Status: Completed
• COG: ARST 0531 - Randomized study of vincristine, dactinomycin and cyclophosphamide (VAC) versus VAC alternating with vincristine and ironotecan (VI) for patients with intermediate-risk rhabdomyosarcoma (RMS), Role: PI, Children Oncology Group, (04/2022 - 04/2023) Status: Completed
• COG ACCL 1333 / BMS CV185-155: a phase III randomized, open label, multi-center study of the safety and efficacy of apixaban for thromboembolism prevention versus no systemic anticoagulant prophylaxis during induction chemotherapy in children with newly diagnosed acute lymphoblastic leukemia (ALL) or lymphoma (T or B cell) treated with Pegylated (PEG) L-asparaginase, Role: PI, Children Oncology Group, (10/2021 - 10/2022) Status: Completed
• COG ADVL1722 / Eisai E7389-G000-223:A phase 2, multicenter, open-label study to assess safety and preliminary activity of eribulin mesylate in pediatric subjects with relapsed/refractory rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) and Ewing sarcoma (EWS), Role: PI, Children Oncology Group, (01/2021 - 01/2022) Status: Completed
• COG AAML1321/Novartis CAMN107A2203: A multi-center, open label, non-controlled phase II study to evaluate efficacy and safety of oral nilotinib in pediatric patients with newly diagnosed Ph+ chronic myelogenous leukemia (CML) in chronic phase (CP) or with Ph+ CML in CP or accelerated phase (AP) resistance or intolerant to either imatibib or dasatinib, Role: PI, Children Oncology Group, (02/2020 - 02/2021) Status: Completed
• COG: AALL05B1 - collecting and banking relapsed acute lymphoblastic leukemia research specimens, Role: PI, Children Oncology Group, (03/2019 - 03/2020) Status: Completed
• COG AOST1321: Phase II study of denosumab (IND #127430, NSC #744010), a RANK ligand antibody, for recurrent or refractory osteosarcoma, Role: PI, Children Oncology Group, (11/2017 - 11/2018) Status: Completed
• COG-ACNS02B3- A children's oncology group protocol for collecting and banking pediatric brain tumor research specimens, Role: PI, Children Oncology Group, (11/2017 - 11/2018) Status: Completed
• COG - ABTR01B1 - A Children's Oncology Group protocol for collecting and banking pediatric research specimens including rare pediatric tumors, Role: PI, Children Oncology Group, (02/2017 - 02/2018) Status: Completed
• COG AAML1522 /Celgene CC -5013-AML-002: a phase 2, multicenter, single-arm, open-label study to evaluate the activity, safety and pharmacokinetics of Lenalidomide (Revlimid®) in pediatric subjects from 1 to less than or equal to 18 years of age with relapsed or refractory acute myeloid leukemia, Role: PI, Children Oncology Group, (01/2017 - 01/2018) Status: Completed
• COG-ACCL1131: A phase III open-label trial of caspofungin vs. azole prophylaxis for patients at high-risk for invasive fungal infections (IFI) following allogeneic hematopoietic cell transplantation (HCT), Role: PI, Children Oncology Group, (04/2016 - 04/2017) Status: Completed
• COG AOST1521: A phase 2 study of GPNMB-targeted antibody-drug conjugate, CDX-011 (glembatumumab vedotin, CR011-vcMMAE; IND #128248, NSC #763737), in recurrent or refractory osteosarcoma, Role: PI, Children Oncology Group, (04/2016 - 04/2017) Status: Completed
• Children's Oncology Group (COG) ACNS0821 - Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent/refractory medulloblastoma/CNS PNET of childhood, a COG randomized phase II screening trial, Role: PI, Children Oncology Group, (10/2015 - 10/2016) Status: Completed
• COG-ANHL1131/EICNHL-IGR2009/1593: Intergroup trial for children or adolescents with B-cell non-Hodgkin lymphoma (NHL) or mature B-cell leukemia (B-AL): Evaluation of rituximab efficacy and safety in high risk patients, Role: PI, Children Oncology Group, (09/2015 - 09/2016) Status: Completed
• COG-AAML0631:Risk adapted treatment of newly diagnosed childhood Acute Promyelocytic leukemia (APL) using Arsenic Trioxide (Trisenox, IND#103,331) during consolidation, Role: PI, Children Oncology Group, (01/2015 - 01/2016) Status: Completed
• NCI - Special exception protocol for chimeric MOAB 14:18 (IND #4308, NSC 623408) pediatric patients, Role: Investigator, National Cancer Institute/NIH/DHHS, (09/2014 - 09/2015) Status: Completed
• COG-ANBL 12P1: pilot study using myeloblative Busulfan/Melphalan (BuMel) consolidation following induction chemotherapy for patients with newly diagnosed high-risk neuroblastoma, Role: PI, Children Oncology Group, (06/2014 - 06/2015) Status: Completed
• Childrens Oncology Group (COG) - ACNS0822: A randomized phase II/III study of vorinostat and local irradiation or temozolomide and local irradiation or bevacizumab and local irradiation followed by maintenance bevacizumab and temozolomide in children with newly diagnosed high-grade gliomas, Role: PI, Children Oncology Group, (04/2014 - 04/2015) Status: Completed
• COG - AALL0232 - high risk B - precursor acute Lymphoblastic Leukemia, Role: PI, Children Oncology Group, (01/2014 - 01/2015) Status: Completed
• COG AALL0433 - Intensive treatment for intermediate-risk relapse of childhood b-precursor acute lymphoblastic leukemia (ALL): a randomized trial of vincristine strategies, Role: PI, Children Oncology Group, (12/2013 - 12/2014) Status: Completed
• COG - AALL1122/BMS - CA180-372: A phase 2 multi-center historically-controlled study of dasatinib added to standard chemotherapy in pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL), Role: Investigator, Children Oncology Group, (11/2013 - 11/2014) Status: Completed
• Children's Oncology Group (COG) - AALL07P1: A phase II pilot trial of bortezomib (PS-341, Velcade®, IND #58,443) in combination with intensive re-induction therapy for children with relapsed acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL), Role: Investigator, Children Oncology Group, (11/2013 - 11/2014) Status: Completed
• COG AREN0321 - Treatment of high risk renal tumors, Role: PI, Children Oncology Group, (11/2013 - 11/2014) Status: Completed
• Children's Oncology Group (COG) - COG - ARST0921: a randomized phase II trial of bevacizumab (avastin) and temsirolimus (torisel) in combination with intravenous vinorelbine and cyclophosphamide in patients with recurrent/refractory rhabdomyosarcoma, Role: PI, Children Oncology Group, (09/2013 - 09/2014) Status: Completed
• COG-AALL0331 - Standard risk B-precursor acute lymphoblastic leukemia, Role: PI, Children Oncology Group, (06/2013 - 06/2014) Status: Completed
• COG # AREN0532 - Treatment for very low, low and standard risk favorable histology Wilms tumor, Role: PI, Children Oncology Group, (05/2013) Status: Completed
• Children's Oncology Group - ANBL1021: feasibility/phase II study of hu14.18-IL2 immunocytokine + GM-CSF and Isotretinoin in patients with relapsed or refractory neuroblastoma, Role: Investigator, Children Oncology Group, (09/2012 - 09/2013) Status: Completed
• COG A3973- A Randomized Study of Purged versus Unpurged Peripheral Blood Stem Cell Transplant Following Dose Intensive Induction Therapy for High Risk Neuroblastoma, Role: PI, Children Oncology Group, (09/2012 - 09/2013) Status: Completed
• COG - ADVL1221: A phase II study of cixutumumab (IMC-A12; IND #100947) in combination with temsirolimus (IND #61010) in pediatric patients with recurrent or refractory solid tumors, Role: Investigator, Children Oncology Group, (07/2012 - 07/2013) Status: Completed
• ANBL0532: Phase III randomized trial of single vs. tandem myeloablative consolidation therapy for high-risk neuroblastoma, Role: PI, Children Oncology Group, (06/2012 - 06/2013) Status: Completed
• Children's Oncology Group (COG) - ANBL0931: A comprehensive safety trial of chimeric antibody 14.18 (ch14.18) with GM-CSF, IL-2 and isotretinoin in high-risk neuroblastoma patients following myeloablative therapy, Role: Investigator, Children Oncology Group, (03/2012 - 03/2013) Status: Completed
• COG - AOST0331, A randomized trial of the European and American Osteosarcoma Study Group to optimize treatment strategies for resectable osteosarcoma based on histologic response to pre-operative chemotherapy (EURAMOS 1), Role: PI, Children Oncology Group, (07/2011 - 07/2012) Status: Completed
• COG-ARST0331,Vincristine, dactinomycin, and lower doses of cyclophosphamide with or without radiation therapy for patients with newly diagnosed low-risk embryonal/botryoid rhabdomyosarcoma, Role: PI, Children Oncology Group, (06/2011 - 06/2012) Status: Completed
• COG -ANBL0531 - Response - and biology-based therapy for intermediate-risk neuroblastoma, Role: PI, Children Oncology Group, (06/2011 - 06/2012) Status: Completed
• COG AAML0531: A phase III randomized trial of gemtuzumab ozogamicin (Mylotarg®) combined with conventional chemotherapy for de novo acute myeloid leukemia (AML) in children, adolescents, and young adults, Role: PI, Children Oncology Group, (06/2011 - 06/2012) Status: Completed
• COG - AGCT0132 - A Phase III study of reduced therapy in the treatment of children with low and intermediate risk extracranial germ cell tumors, Role: PI, Children Oncology Group, (05/2011 - 05/2012) Status: Completed
• AALL02P2, Treatment of late isolated extramedullary relapse from acute lymphoblastic leukemia (ALL) (Initial CR1=18months), Role: PI, Children Oncology Group, (05/2011 - 05/2012) Status: Completed
• COG-AHOD0031-A phase III group-wide study of dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate risk Hodgkin Disease, Role: PI, Children Oncology Group, (12/2010 - 12/2011) Status: Completed
• COG: ADVL04P2 - A feasibility pilot and phase 2 study of chemoimmunotherapy with epratuzumab for children with relapsed CD22-positive acute lymphoblastic leukemia, Role: PI, Children Oncology Group, (12/2010) Status: Completed
• COG - ACNS0221 - A phase II study of conformal radiotherapy in patients with low-grade gliomas, Role: Investigator, Children Oncology Group, (10/2010 - 10/2011) Status: Completed
• COG: AHOD 0521 - A phase II study to bortezomib (velcade, PS-341, IND #58443) in combination with ifosfamide/vinorelbine in pediatric patients and young adults with refractory/recurrent Hodgkin disease, Role: PI, Children Oncology Group, (07/2010 - 07/2011) Status: Completed
• COG - ANHL0131 - A Phase III trial of treatment of advanced-stage anaplastic large cell lymphoma (ALCL) with standard APO (doxorubicin, prednisone, vincristine) versus consolidation with a regimen including vinblastine, Role: Investigator, Children Oncology Group, (08/2009 - 08/2010) Status: Completed
• COG-ANHL01P1 - A pilot study to determine the toxicity of the addition of rituximab to the induction and consolidation phases and the addition of rasburicase to the reduction phase in children with newly diagnosed advanced B-cell leukemia/lymphoma treated with LMB/FAB therapy., Role: Investigator, Children Oncology Group, (06/2009 - 06/2010) Status: Completed
• COG-ARST0321 - A phase II study of sulindac and tamoxifen in patients with desmoid tumors that are recurrent or not amenable to standard therapy, Role: Investigator, Children Oncology Group, (03/2009 - 03/2010) Status: Completed
• COG - AHOD0431, A Phase III study for the treatment of children and adolescents with newly diagnosed low risk Hodgkin Disease, Role: PI, Children Oncology Group, (01/2009 - 01/2010) Status: Completed
• COG-AEWS02B1 - A groupwide biology and banking study for Ewing Sarcoma, Role: Investigator, Children Oncology Group, (11/2008 - 11/2009) Status: Completed
• COG-AAML0122 - Phase II window evaluation of the farnesyl transferase inhibitor (R115777) followed by 13-CIS Retinoic Acid, Cytosine Arabinoside and Fludarabine plus Hematopoietic stem cell transplantation in children with juvenile myelomonocytic leukemia, Role: Investigator, Children Oncology Group, (10/2008 - 10/2009) Status: Completed
• COG - AAML03P1 - Treatment of newly diagnosed childhood AML using intensive MRC-based therapy and Gemtuzumab Ozogamicin (GMTZ): A COG pilot study, Role: Investigator, Children Oncology Group, (10/2008 - 10/2009) Status: Completed
• COG-ARST 0431 intensive ,multi-agent therapy, including dose-compressed cycles of ifosfamide/etoposide (IE) and vincristine/doxorubicin/cyclophosphamide (VDC) for patients with high-risk rhabdomyosarcoma, Role: Investigator, Children Oncology Group, (08/2008 - 08/2009) Status: Completed
• COG - ACNS0121 - A Phase II trial of conformal radiation therapy for pediatric patients with localized ependymoma, chemotherapy prior to second surgery for incompletely resected ependymoma and observations for completely resected, differentiated, supratentorial ependymoma, Role: PI, Children Oncology Group, (08/2008 - 08/2009) Status: Completed
• Children's Oncology Group (COG) Protocol #ACNS0232: Radiotherapy alone versus chemotherapy followed by response-based radiotherapy for newly diagnosed primary CNS germinoma, Role: Investigator, Children Oncology Group, (07/2008 - 07/2009) Status: Completed
• COG-AEWS0031 Trial of chemotherapy intensification through interval compression in Ewing sarcoma and related tumors, Role: PI, Children Oncology Group, (05/2008 - 05/2009) Status: Completed
• COG - ACNS0122, A Phase II study to assess the ability of neoadjuvant chemotherapy +/- second look surgery to eliminate all measurable disease prior to radiotherapy for NGGCT, Role: Investigator, Children Oncology Group, (05/2008 - 05/2009) Status: Completed
• CCG - ARST0121 - A groupwide randomized phase II window study of two different schedules of Irinotecan in combination with Vincristine and pilot assessment of safety and efficacy of Tirapazamine combined with multiagent chemotherapy for first relapse or progressive disease in Rhabdomyosarcoma and related tumors, Role: Investigator, Children Oncology Group, (04/2008 - 04/2009) Status: Completed
• COG-AALL0031 - A Children's Oncology Group pilot study for the treatment of very high risk Acute Lymphoblastic Leukemia in children and adolescents, Role: Investigator, Children Oncology Group, (04/2008 - 04/2009) Status: Completed
• COG - AALL01P2 - Intensive induction therapy for children with Acute Lymphoblastic Leukemia (ALL) who experience a bone marrow relapse, Role: Investigator, Children Oncology Group, (04/2008 - 04/2009) Status: Completed
• Children's oncology group (COG) protocol #AGCT01P1- Pilot study of cisplatin, etoposide, bleomycin and escalating dose cyclophosphamide therapy for children with high-risk malignant germ cell turmors, Role: Investigator, Children Oncology Group, (04/2008 - 04/2009) Status: Completed
• COG- ANBL0421 -A phase II study of irinotecan + temozolomide in children with recurrent neuroblastoma, Role: Investigator, Children Oncology Group, (03/2008 - 03/2009) Status: Completed
• COG-AHOD0321 - A phase II study of weekly gemcitabine and vinorelbine in children with recurrect or refractory hodgkin disease, Role: Investigator, Children Oncology Group, (03/2008 - 03/2009) Status: Completed
• Children's Oncology Group (COG) Protocol # AEWS02P1 - A pilot study of low-dose antiangiogenic chemotherapy in combination with standard multiagent chemotherapy for patients with newly diagnosed Ewing Sarcoma family of tumors, Role: Investigator, Children Oncology Group, (02/2008 - 02/2009) Status: Completed
• Children's Oncology Group (COG) Protocol #ANHL0221 - a Phase II study of the combination of cyclophosphamide, prednisone and rituximab (CPR) in children, adolescents and young adults with CD20 positive post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation (SOT), Role: Investigator, Children Oncology Group, (01/2008 - 01/2009) Status: Completed
• COG-AOST0221 - A Phase II study of aerosolized GM-CSF (NSC# 613795, IND# 11042) in patients with first pulmonary recurrence of osteosarcoma, Role: Investigator, Children Oncology Group, (01/2008 - 01/2009) Status: Completed
• COG-ACNS0126 - A Phase II study of Temozolomide in the treatment of children with high-grade glioma, Role: Investigator, Children Oncology Group, (12/2006 - 12/2007) Status: Completed
• COG-AOST0121 - A Groupwide Phase II Study of Trastuzumab (Herceptin) in Metastatic Osteosarcoma Patients with Tumors that Overexpress Her2, Role: Investigator, Children Oncology Group, (03/2006 - 03/2007) Status: Completed
• COG - P9934 - Systemic chemotherapy, second look surgery and conformal radiation therapy limited to the posterior fossa and primary site for children > 8 months and < 3 years with non-metastatic medulloblastoma, Role: Investigator, Children Oncology Group, (07/2005 - 07/2006) Status: Completed
• COG-AALL01B1, Multiparameter flow cytometry for assessment of early marrow response in pediatric acute lymphoblastic leukemia: a companion study to CCG-1991, Role: Investigator, Children Oncology Group, (05/2005 - 05/2006) Status: Completed
• COG - AALL00P2, The use of modified BFM +/- compound 506U78 in an intensive chemotherapy regimen for the treatment of T-cell leukemia, Role: Investigator, Children Oncology Group, (03/2005 - 03/2006) Status: Completed
• COG - ACNS02B2 - Preclinical analysis of CD 155 and an intergeneric poliovirus in pediatric brain tumor specimens, Role: Investigator, Children Oncology Group, (02/2005 - 02/2006) Status: Completed
• COG - ADVL0023 - A Phase II study of Docetaxel (Taxotere) (NSC#628503) in children with refractory leukemias, Role: Investigator, Children Oncology Group, (01/2005 - 01/2006) Status: Completed
• COG-ACNS0226- A Phase II study of R115777 (ZARNESTRA) (NSC#702818, IND#58359) in children with recurrent or progressive high grade Glioma, Medulloblastoma/PNET or brainstem Glioma, Role: Investigator, Children Oncology Group, (12/2004 - 12/2005) Status: Completed
• COG-ALTE02C1 - Quality of life in children who have survived neuroblastoma, Role: Investigator, Children Oncology Group, (11/2004 - 11/2005) Status: Completed
• COG-ADVL0122 - A phase II trial of Gleevec (imatinib mesylate, formerly ST1571) in children with refractory or relapsed solid tumors, Role: Investigator, Children Oncology Group, (07/2004 - 07/2005) Status: Completed
• COG-A2971 - Treatment of children with Down Syndrome and Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Transient Myeloproliferative Disorder, Role: Investigator, Children Oncology Group, (07/2004 - 07/2005) Status: Completed
• COG-ASCT0031 - A phase III trial of hydroxychloroquine + standard therapy for chronic graft-versus-host disease, Role: Investigator, Children Oncology Group, (06/2004 - 06/2005) Status: Completed
• COG AE-22. A case-control study of malignant germ cell tumors (GCT) in children, Role: Investigator, National Cancer Institute/NIH/DHHS, Status: Completed
• CCG-A0026 Case control study of risk factors for Wilms tumor, Role: Investigator, Children Oncology Group, Status: Completed
• COG-ADVL0022 - A Phase II study of Gemcitabine (NSC # 613327) in children with relapsed acute lymphoblastic leukemia or acute myelogenous leukemia, Role: Investigator, Children Oncology Group, Status: Completed

For Profit Organization

• COG ADVL1822/ Daiichi Sankyo, Inc. AC220-A-U202: A Phase 1/2, Multicenter, Dose-Escalating study to evaluate the safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Quizartinib administration in combination with re-induction chemotherapy, and as a single-agent continuation therapy, in pediatric relapsed/refractory AML subjects ages 1 month to <18 years (and Young adults ages up to 21 years) with FLT3-ITB mutations, Role: PI, Daiichi Sankyo Pharma Development, (06/2024 - 06/2025) Status: Approved
• CCG D9902 A group wide protocol for collecting and banking pediatric cancer research specimens. An intergroup rhabdomyosarcoma study group protocol., Role: PI, Children Cancer Group, (05/2023 - 05/2024) Status: Completed
• EAP-Oncoceutics-ONC018: Expanded access to ONC201 for patients with H3 K27M-mutant and/or midline high grade gliomas, Role: PI, Oncoceutics, Inc., (10/2022 - 10/2023) Status: Completed
• Jazz Pharmaceuticals JZP458-201 (COG AALL1931): An open-label, multicenter study of RC-P in patients with acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL) following hypersensitivity to E. coli-derived asparaginases, Role: PI, Jazz Pharmaceuticals, (01/2022 - 01/2023) Status: Completed
• Pfizer B0661037: A randomized, open-label, active controlled, safety and descriptive efficacy study in pediatric subjects requiring anti-coagulation for the treatment of a venous thromboembolic event, Role: PI, Pfizer Inc., U.S. Pharmaceuticals Group, (11/2021 - 11/2022) Status: Completed
• Pfizer FRAG-A001-201 (A6301094): A three month prospective open label study of therapy with Fragmin® ( Dalteparin sodium injection) in children with venous thromboembolism with or without malignancies, Role: PI, Pfizer Inc., U.S. Pharmaceuticals Group, (05/2017 - 05/2018) Status: Completed
• Center for international blood and marrow transplant research (CIBMTR) - 09-MRD: The role of minimal residual disease testing before and after hematopoietic cell transplantation for pediatric acute myeloid leukemia, Role: PI, Center for International Blood and Marrow Transplant Research, (12/2016 - 12/2017) Status: Completed
• Compassionate Use of open-label PKC412 patient with aggressive mast cell sarcoma, Role: PI, Novartis Pharmaceuticals Corporation, (08/2014 - 08/2015) Status: Completed
• A 3-year, prospective, non-interventional, multicenter registry in Sickle Cell disease, Role: PI, Novartis Pharmaceuticals Corporation, (07/2013 - 07/2014) Status: Completed
• VariZIG expanded access protocol (VZ-009) safety and efficacy of varicella zoster immune globulin (Human) (VariZIG™) in patients at-risk of varicella infection, Role: Investigator, Cangene Corporation, (12/2012 - 12/2013) Status: Completed
• Biovitrum - 20010133 - A Phase I dose-escalation study to evaluate the safety and pharmacokinetics (PK) of palifermin in pediatric subjects with acute leukemias undergoing myeloablative therapy and allogeneic hematopoietic stem cell transplant (HSCT), Role: Investigator, Amgen, Inc., (02/2011 - 02/2012) Status: Completed
• Novartis ICL670670A109E1-A one year open label, non-comparative extension to a randomized, multicenter, phase II study to evaluate the safety, tolerability, pharmacokinetics and the effects on liver iron concentration of repeated doses of 5-30mg/kg/day of ICL670 relative to deferoxamine in sickle cell disease patients with transfusional hemosiderosis, Role: Investigator, Novartis Pharmaceuticals Corporation, (12/2008 - 12/2009) Status: Completed
• CCG-P9754 protocol for patients with newly-diagnosed non-metastatic osteosarcoma, Role: Investigator, Children Cancer Group, (10/2008 - 10/2009) Status: Completed
• CCF 1961. Treatment of patients with acute lymphoblastic leukemia with unfavorable features, Role: Investigator, Children's Cancer Study Group, (10/2008 - 10/2009) Status: Completed
• CCG-L9704 Quality of life following successful therapy for acute myelegenous leukemia: a comparison of bone marrow and chemotherapy, Role: Investigator, Children Cancer Group, (10/2008 - 10/2009) Status: Completed
• CCG D9803 Randomized study of vincristine, actinomycin-D, and cyclophosphamide V(AC) versus VAC alternating with vincristine, topotecan and cyclophosphamide for patients with intermediate-risk rhabdomyosarcoma, Role: Investigator, Children Cancer Group, (10/2008 - 10/2009) Status: Completed
• CCG 4941. National Wilms Tumor Study - 5: Therapeutic trial and biology study, Role: Investigator, Children's Cancer Study Group, (09/2008 - 09/2009) Status: Completed
• Hemophilia and Thrombosis Research Society Registry, Role: Investigator, Hemophilia and Thrombosis Research Society, Inc., (05/2008 - 05/2009) Status: Completed
• CCG 2961. Treatment of acute myeloid leukemia or melodysplastic syndrome, Role: Investigator, Children's Cancer Study Group, (04/2008 - 04/2009) Status: Completed
• CCG A9952. Chemotherapy for progressive low grade astrocytoma in children less than ten years old, Role: Investigator, Children's Cancer Study Group, (04/2008 - 04/2009) Status: Completed
• CCG D9602. Actinomycin D and Vincristine with or without radiation therapy for newly diagnosed patients with low-risk rhabdomyosarcoma or undifferentiated sarcoma: An IRS-V protocol, Role: Investigator, Children Cancer Group, (04/2008 - 04/2009) Status: Completed
• CCG-A5971 - Randomized phase III study for the treatment of newly diagnosed disseminated lymphoblastic lymphoma or localized lymphoblastic lymphoma, Role: PI, Children Cancer Group, (04/2008 - 04/2009) Status: Completed
• CCG A3961. Treatment for infants and children with intermediate risk neuroblastoma, Role: Investigator, Children's Cancer Study Group, (03/2008 - 03/2009) Status: Completed
• Study No. CICL670A2201 - A randomized, open-label, multi-center, phase II study to evaluate the safety and efficacy of oral ICL670 (deferasirox) 20 mg/kg/day relative to subcutaneous deferoxamine in sickle cell disease patients with iron overload from repeated blood transfusions, Role: Investigator, Novartis Pharmaceuticals Corporation, (02/2008 - 02/2009) Status: Completed
• CCG-P9851 Osteosarcoma biology protocol: companion to intergroup studies, Role: Investigator, Children Cancer Group, (02/2008 - 02/2009) Status: Completed
• CCG-P9641. Primary surgical therapy for biologically defined low-risk neuroblastoma, Role: PI, Children Cancer Group, (01/2008 - 01/2009) Status: Completed
• CCG P9645 Intergroup protocol for treatment of children with hepatoblastoma, Role: PI, Children Cancer Group, (01/2008 - 01/2009) Status: Completed
• Schering-Plough Research Institute Protocol #P02095 - open label, limited access protocol of Posaconazole in invasive fungal infections, Role: PI, Schering Plough, (05/2007 - 05/2008) Status: Completed
• CCG-5941: Pilot study of the treatment of disseminated anaplastic large cell Ki-1 lymphoma and T-large cell lymphoma, Role: Investigator, Children's Cancer Study Group, (01/2007 - 01/2008) Status: Completed
• CCG-B961 Prognostic significance of KI-67 proliferative index utilizing the MIB-1 antibody in low grade gliomas in young children., Role: Investigator, Children's Cancer Study Group, (02/2006 - 02/2007) Status: Completed
• CCG B971 Molecular biology of pediatric brain tumors, Role: Investigator, Children's Cancer Study Group, (05/2005 - 05/2006) Status: Completed
• CCG B957 Genetic etiology of acute leukemia in Down syndrome, Role: Investigator, Children Cancer Group, (02/2005 - 02/2006) Status: Completed
• CCG B947 A group-wide protocol for collecting tumor specimens, Role: Investigator, Children's Cancer Study Group, (09/2004 - 09/2005) Status: Completed
• CCG-S9801 A study second malignant neoplasms following childhood cancer, Role: Investigator, Children Cancer Group, (06/2004 - 06/2005) Status: Completed
• CCG 4942 "National Wilm's Tumor Study-5" Treatment of relapsed patients, Role: Investigator, Children Cancer Group, (09/2001 - 09/2002) Status: Completed
• CCG-P9462 - Randomized treatment for refractory neuroblastoma with topotecan regimens, following deferoxamine (POG only) in an investigational window, Role: Investigator, Children Cancer Group, (09/2001 - 09/2002) Status: Completed
• CCG B944 Biology studies in Hodgkin's and non-Hodgkin's lymphoma, Role: Investigator, Children's Cancer Study Group, (02/2001 - 02/2002) Status: Completed
• CCSG-E13. Case-control study of Hodgkin's disease in childhood, Role: Investigator, Children's Cancer Study Group, Status: Completed
• CCG B945 Genetic epidemiology of leukemia in infants and young children, Role: Investigator, Children's Cancer Study Group, Status: Completed
• CCG B951 Pharmacological studies of L-asparaginase in pediatric patrients with ALL, Role: Investigator, Children's Cancer Study Group, Status: Completed
• CCG AE-24 Epidemiology of infant leukemia, Role: Investigator, Children Cancer Group, Status: Completed
• CCG E-23 Epidemiology of Down-syndrome leukemia and Down syndrome, Role: Investigator, Children Cancer Group, Status: Completed
• CCG AE25 Pesticides and VDJ-recombination mutations in childhood NHL, Role: Investigator, Children Cancer Group, Status: Completed
• CCG-D9802. "Up-Front Window Study" of Irinotecan (CPT-11) Combined with Vincristine Followed by Multimodal, Multiagent Therapy for Selected Children and Adolescents with Newly Diagnosed Stage 4/Clinical Group IV Rhabdomyosarcoma: an IRS-V Study, Role: Investigator, Children Cancer Group, Status: Completed
• CCG B972 Immune status and activation in children participating in CCG-2961 "A phase III trial in children with untreated acute myelogeneus leukemia leukemia (AML) or myelodysplastic syndrome, Role: Investigator, Children Cancer Group, Status: Completed

Foreign

• Pediatric blood and marrow transplant consortium (PBMTC) and Canadian Institutes of Health Research (CIHR) - GVHD-1202: Predictive biomarkers for pediatric chronic graft-versus-host disease, Role: PI, Canadian Institutes of Health Research, (09/2024 - 09/2025) Status: Approved

Internal

• A randomized controlled trial comparing daily oral iron administration to every alternate day iron administration in the treatment of iron deficiency anemia in pediatric patients, Role: PI, LLU Dept. of Pediatrics, (08/2024) Status: Approved
• Using Virtual Reality to Alleviate Pain and Anxiety in Pediatric Oncology Patients, Role: Investigator, LLU Dept. of Pediatrics, (10/2022) Status: Approved
• Tumor cell bank, Role: PI, LLU Dept. of Pediatrics, (04/2016 - 04/2017) Status: Completed
• CHLA-Head start III-Dose intensive chemotherapy for children less than 10 years of age newly diagnosed with malignant brain tumors: A Pilot Study of two alternative Intensive Induction Chemotherapy Regimens, followed by Consolidation with Myeloablative Chemotherapy (Thiotepa and Carboplatin, with or without Etoposide) and Autologous Stem Cell Rescue, Role: PI, LLU Dept. of Pediatric Oncology, (04/2016 - 04/2017) Status: Completed
• Compassionate use of desatinib for pediatric patients with leukemia and have failed gleevec, Role: Investigator, LLU Cancer Institute, Status: Completed
• LLU Cancer Center biospecimen laboratory - specimens collection protocol, Role: Investigator, LLU Cancer Institute, (09/2024 - 09/2025) Status: Approved

Non-Profit Organization

• The National Marrow donor Program (NMDP) and Center for International Blood and Marrow Transplant Research (CIBMTR) - Contribution of a Blood Sample to the National Marrow Donor Program's Research Sample Repository, Role: Investigator, National Marrow Donor Program, (09/2024 - 09/2025) Status: Approved
• PTCTC ONC1701 (End RAD): A phase II pilot trial to estimate survival after a non-total body irradiation (TBI) based on conditioning regimen in patients diagnosed with B-acute lymphoblastic leukemia (ALL) who are pre-allogeneic hematopoietic cell transplantation (HCT) next-generation-sequence (NGS) minimal residual disease (MRD) negative, Role: Investigator, Pediatric Blood and Marrow Transplant Consortium, (06/2024 - 06/2025) Status: Approved
• NMDP and CIBMTR - Protocol for Research Database for Hematopoietic Stem Cell Transplantation and Marrow Toxic Injuries., Role: Investigator, National Marrow Donor Program, (06/2024 - 06/2025) Status: Approved
• St. Baldrick's Foundation Infrastructure Grant, Role: PD/PI, St. Baldrick's Foundation, (01/2024 - 12/2024) Status: Awarded
• Infrastructure funding for Pediatric Cancer Research at LLUCH, Role: PD/PI, St. Baldrick's Foundation, (01/2023 - 12/2024) Status: Closed
• Support for the LLUCC Pediatric Oncology Clinical Research Unit, Role: PD/PI, St. Baldrick's Foundation, (01/2020 - 12/2020) Status: Closed
• Improved Infrastructure to participate in selected COG studies, Role: PD/PI, St. Baldrick's Foundation, (01/2018 - 12/2018) Status: Closed
• Infrastructure Support for LLUCC Pediatric Oncology Research, Role: PD/PI, St. Baldrick's Foundation, (01/2017 - 12/2017) Status: Closed
• St Baldricks Infrastructure Grant for Pediatric Clinical Oncology Research- LLUMC, Role: Principal Investigator, St. Baldrick's Foundation, (01/2016 - 12/2016) Status: Closed
• Everychild (APEC14B1) PCR- COG Foundation, Role: Principal Investigator, Children's Hospital Philadelphia, (10/2015 - 10/2020) Status: Closed
• (MAS) Multiple Children's Oncology Group for Non-Industry Funding Sources, Role: PD/PI, Children's Hospital Philadelphia, (10/2012 - 04/2022) Status: Closed
• (MAS) Multiple Children's Oncology Group for Non-Industry Funding Sources, Role: Principal Investigator, Children's Hospital Philadelphia, (10/2012 - 04/2022) Status: Closed
• (MAS) Multiple Children's Oncology Group for Non-Industry Funding Sources, Role: Subproject PI, Children's Hospital Philadelphia, (10/2012 - 04/2022) Status: Closed
• BMS Study CA 124-002 - A Phase II randomized non-comparative trial of Irinotecan and Carboplatin vs Irinotecan in subjects 1-21 years of age with refractory solid tumors, Role: Investigator, Bristol-Myers Squibb Foundation, Inc., Status: Completed
• BMS Study CA 124-003 - A study to document long-term safety and continued benefit of Irinotecan and Carboplatin or Irinotecan in subjects 1-21 years of age with refractory solid tumors who have experienced clinical benefit following a minimum of 6 cycles of therapy on BMS protocol CA 124001 or BMS CA 124002, Role: Investigator, Bristol-Myers Squibb Foundation, Inc., Status: Completed
• National Marrow Donor Program® (NMDP) - 10-CBA: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications, Role: Investigator, National Marrow Donor Program, (09/2024 - 09/2025) Status: Approved
• St. Baldrick's Infrastructure Grant 2025, Role: PD/PI, St. Baldrick's Foundation, (01/2025 - 12/2025) Status: Awarded